Rhythm Pharmaceuticals (RYTM) to Release Earnings on Tuesday

Key Points

• Rhythm Pharmaceuticals is set to release its Q2 2025 earnings results on August 5th, with analysts predicting an earnings loss of ($0.64) per share and revenue of $43.72 million.
• In its last earnings report, Rhythm missed estimates, reporting a loss of ($0.81) per share and revenue of $37.72 million, highlighting a negative net margin of 123.26%.
• The stock price is currently at $85.68, with multiple analysts maintaining a "buy" rating and setting target prices between $80 and $95.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.64) per share and revenue of $43.72 million for the quarter.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.12). The business had revenue of $37.72 million during the quarter, compared to analyst estimates of $40.43 million. Rhythm Pharmaceuticals had a negative return on equity of 739.62% and a negative net margin of 123.26%. Rhythm Pharmaceuticals's revenue was up 25.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.35) EPS. On average, analysts expect Rhythm Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Rhythm Pharmaceuticals Price Performance

NASDAQ RYTM traded up $3.07 during trading on Friday, hitting $88.30. The company's stock had a trading volume of 666,964 shares, compared to its average volume of 673,122. Rhythm Pharmaceuticals has a fifty-two week low of $40.61 and a fifty-two week high of $94.80. The company has a market cap of $5.62 billion, a PE ratio of -31.42 and a beta of 2.26. The business's 50 day simple moving average is $71.41 and its 200-day simple moving average is $62.01.

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, insider Pamela J. Cramer sold 15,572 shares of the stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $77.13, for a total transaction of $1,201,068.36. Following the transaction, the insider owned 19,209 shares of the company's stock, valued at approximately $1,481,590.17. This represents a 44.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alastair Garfield sold 1,319 shares of the stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $64.81, for a total value of $85,484.39. Following the transaction, the insider directly owned 3,126 shares in the company, valued at approximately $202,596.06. The trade was a 29.67% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 81,417 shares of company stock worth $6,352,511. Insiders own 6.10% of the company's stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

An institutional investor recently raised its position in Rhythm Pharmaceuticals stock. AQR Capital Management LLC increased its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 148.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,363 shares of the company's stock after acquiring an additional 23,506 shares during the period. AQR Capital Management LLC owned about 0.06% of Rhythm Pharmaceuticals worth $2,085,000 at the end of the most recent quarter.

Analyst Ratings Changes

A number of research firms have recently commented on RYTM. JMP Securities restated a "market outperform" rating and issued a $84.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Thursday, June 26th. Wells Fargo & Company boosted their price objective on Rhythm Pharmaceuticals from $91.00 to $129.00 and gave the company an "overweight" rating in a research report on Thursday, July 10th. Leerink Partnrs upgraded Rhythm Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 7th. Wall Street Zen upgraded Rhythm Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, July 26th. Finally, Bank of America boosted their price target on Rhythm Pharmaceuticals from $73.00 to $95.00 and gave the stock a "buy" rating in a research report on Thursday, July 10th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $91.93.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.